{
    "response": "**Overall Treatment Decision:** Yes\u2014initiate\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Disabling multifocal CNS relapse suspected Early steroids improve recovery No clinical or laboratory evidence of sepsis (CRP low, stable vitals)\n\n*   **Treatment:** Proton pump inhibitor for gastric protection\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastroprotection during high-dose steroids\n\n*   **Treatment:** Physiotherapy and falls precautions\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Ataxic gait and imbalance Prevention of deconditioning and injury\n\n*   **Treatment:** Oral baclofen for spasticity\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Bilateral spasticity with clonus Symptomatic relief and improved mobility\n\n*   **Treatment:** Plasma exchange (5\u20137 sessions)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for steroid-refractory attack Particularly effective in NMOSD/MOGAD or severe deficits\n\n*   **Treatment:** Targeted antimicrobial therapy\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start only if CSF/imaging support rhombencephalitis or another infection Avoid unnecessary antibiotics given low inflammatory markers\n\n*   **Treatment:** Disease-modifying therapy for confirmed diagnosis (e.g., MS DMT or rituximab for NMOSD)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Requires definitive diagnosis and phenotyping Choice depends on antibody status and MRI findings\n\n*   **Treatment:** Venous thromboembolism prophylaxis with LMWH if mobility reduced\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Impaired mobility increases VTE risk\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Disabling multifocal CNS relapse suspected\", \"Early steroids improve recovery\", \"No clinical or laboratory evidence of sepsis (CRP low, stable vitals)\"]}, {\"treatment\": \"Proton pump inhibitor for gastric protection\", \"timing\": \"Start Now\", \"reasons\": [\"Gastroprotection during high-dose steroids\"]}, {\"treatment\": \"Physiotherapy and falls precautions\", \"timing\": \"Start Now\", \"reasons\": [\"Ataxic gait and imbalance\", \"Prevention of deconditioning and injury\"]}, {\"treatment\": \"Oral baclofen for spasticity\", \"timing\": \"Start Now\", \"reasons\": [\"Bilateral spasticity with clonus\", \"Symptomatic relief and improved mobility\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 sessions)\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for steroid-refractory attack\", \"Particularly effective in NMOSD/MOGAD or severe deficits\"]}, {\"treatment\": \"Targeted antimicrobial therapy\", \"timing\": \"Delay\", \"reasons\": [\"Start only if CSF/imaging support rhombencephalitis or another infection\", \"Avoid unnecessary antibiotics given low inflammatory markers\"]}, {\"treatment\": \"Disease-modifying therapy for confirmed diagnosis (e.g., MS DMT or rituximab for NMOSD)\", \"timing\": \"Delay\", \"reasons\": [\"Requires definitive diagnosis and phenotyping\", \"Choice depends on antibody status and MRI findings\"]}, {\"treatment\": \"Venous thromboembolism prophylaxis with LMWH if mobility reduced\", \"timing\": \"Start Now\", \"reasons\": [\"Impaired mobility increases VTE risk\"]}]"
}